Our Pipeline
At MBX, we are reimagining how patients live with endocrine and metabolic diseases.
Enabled by our proprietary PEPTM platform technology, we have a growing pipeline of therapeutic candidates in various stages of clinical development.
Our pipeline of PEP candidates includes clinically validated targets with well-defined regulatory pathways to address significant unmet medical needs. We believe our efforts will make a meaningful impact in improving the lives of individuals living with endocrine and metabolic disorders.
Development Programs
More information on our Phase 3 oPTimize trial evaluating the safety and efficacy of canvuparatide (MBX 2109) can be found here.
Canvuparatide (MBX 2109) is an investigational new drug (delivered via sub-cutaneous injection), that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed canvuparatide to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration.
Full Phase 2 results and one-year open label extension data from our Phase 2 Avail trial were presented at ENDO 2026. Results demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy through one year, with findings consistent with restoration of systemic PTH activity through normalization of serum calcium, reduction of urine calcium excretion and restoration of bone metabolism, as well as a safety profile and pharmacokinetics supporting once-weekly dosing. More information can be found in the Presentations section of our website.
Hypoparathyroidism Background
Parathyroid hormone (PTH) is a peptide hormone secreted by the parathyroid glands that regulates calcium and phosphate levels in the blood through its effects on bone, kidneys and intestines. The parathyroid glands are located behind the thyroid gland in the neck.
Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of PTH. It affects more than 260,000 persons throughout the United States, Europe and Japan.1-3 HP is often caused by damage to, or removal of, the parathyroid glands during surgery for another condition. It can also be caused by an autoimmune process or other etiologies. Insufficient PTH results in a lowering of blood calcium levels (hypocalcemia) and an increase in phosphate levels (hyperphosphatemia).
Hypocalcemia can cause a variety of symptoms ranging in intensity from mild to severe, including muscle cramps and spasms in the hands and feet and numbness or tingling around the mouth and fingers and toes.4 Depression, confusion and loss of memory have been reported5 and certain individuals may develop calcium deposits in the brain or the kidneys, which can lead to impairment of kidney function.4,6,7 Persons with HP may also be more prone to developing kidney stones.4,7 Less often, more serious complications can occur including seizures or cardiac arrhythmias (abnormal heartbeat).7,8 Consequently, HP can greatly impact a person’s quality of life, interfere with their daily lives, and negatively impact their ability to work.9
Treatment of HP is aimed at raising calcium levels in the blood to provide relief of symptoms without causing abnormally high levels of calcium in the blood (hypercalcemia) or urine (hypercalciuria). The mainstay of treatment is calcium supplements and active vitamin D. Long-term use of these can contribute to the development of calcium deposits and kidney stones.
* The results observed from preclinical studies or early-stage clinical trials of our product candidates may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. Similarly, positive results from such preclinical studies or early-stage clinical trials may not be replicated in our subsequent preclinical studies or clinical trials.
Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent PEP™ GLP-1/GIP co-agonist prodrug with the goal of potential once-monthly dosing frequency and improved efficacy and tolerability relative to existing standards of care. Our goal is to help individuals achieve healthier lives by addressing the underlying mechanisms contributing to excess weight and metabolic imbalance. MBX 4291 is currently in Phase 1 clinical evaluation, focusing on safety, tolerability, and pharmacokinetics in adult participants with obesity. More information in the Phase 1 trial design can be found here.
In May 2026, we provided an obesity portfolio update, including initial Phase 1 data for MBX 4291 supporting the potential for once-monthly dosing.
2026 Obesity Day Press Release
2026 Obesity Day Presentation
Obesity is a common condition in the United States, with more than 2 in 5 adults 20 and older (42.5%)1 being afflicted. A chronic condition, it can be caused by a variety of factors including, but not limited to, eating high-calorie, low nutrient foods and beverages, lack of physical activity, some medications, and genetics.
Screening for obesity is performed by healthcare providers using body mass index (BMI), which measures the percent of body fat in an individual. A person whose weight is higher than what is considered to be a normal weight for a given height is described as being overweight or having obesity.2 In the case of adults 20 and older, a BMI >30 is classified as obese and >40 is severely obese.
A high percentage of body fat can put an individual’s health at risk as it increases the likelihood for developing more than 200 health problems such as high blood pressure, type 2 diabetes, depression, cancer and heart disease – the leading cause of death in the United States. In fact, research shows that there has been a three-fold increase in obesity-related deaths from heart disease in the United States between 1999-2020.3
The biomedical, psychosocial, and economic consequences of obesity have substantial implications for the health and well-being of the U.S. population.4 There is also a bias to be addressed, as it is well documented that those who feel stigmatized by obesity can suffer extreme emotional distress and be subject to discrimination, which can lead to further negative health impacts, including depression and additional weight gain.5
While lifestyle changes may influence weight loss and reductions in BMI, obesity is a complex problem that often does not have a single solution. Whether behavioral, pharmacologic, or surgical, this epidemic may benefit from a holistic multifaceted approach.6
We are developing a portfolio of treatments designed to address the broad range of obesity patient needs. In addition to MBX 4291, the Company announced the nomination of MBX 5765 as its lead amycretin prodrug candidate. Enabled by our clinically validated PEP™ platform, MBX 5765 combines GLP-1, GIP, glucagon, and dual amylin and calcitonin receptor agonist (DACRA) activity in a single construct. The differentiated mechanism of MBX 5765 is designed for once-monthly dosing, superior efficacy and improved tolerability. IND-enabling studies are ongoing.
2026 Obesity Day Press Release
2026 Obesity Day Presentation
Obesity is a common condition in the United States, with more than 2 in 5 adults 20 and older (42.5%)1 being afflicted. A chronic condition, it can be caused by a variety of factors including, but not limited to, eating high-calorie, low nutrient foods and beverages, lack of physical activity, some medications, and genetics.
Screening for obesity is performed by healthcare providers using body mass index (BMI), which measures the percent of body fat in an individual. A person whose weight is higher than what is considered to be a normal weight for a given height is described as being overweight or having obesity.2 In the case of adults 20 and older, a BMI >30 is classified as obese and >40 is severely obese.
A high percentage of body fat can put an individual’s health at risk as it increases the likelihood for developing more than 200 health problems such as high blood pressure, type 2 diabetes, depression, cancer and heart disease – the leading cause of death in the United States. In fact, research shows that there has been a three-fold increase in obesity-related deaths from heart disease in the United States between 1999-2020.3
The biomedical, psychosocial, and economic consequences of obesity have substantial implications for the health and well-being of the U.S. population.4 There is also a bias to be addressed, as it is well documented that those who feel stigmatized by obesity can suffer extreme emotional distress and be subject to discrimination, which can lead to further negative health impacts, including depression and additional weight gain.5
While lifestyle changes may influence weight loss and reductions in BMI, obesity is a complex problem that often does not have a single solution. Whether behavioral, pharmacologic, or surgical, this epidemic may benefit from a holistic multifaceted approach.6
In August 2026, we nominated MBX 6180 as our lead GLP-1/GIP/glucagon (GCG) triple agonist prodrug candidate, further expanding our obesity pipeline to potentially address the full spectrum of patient needs. MBX 6180 combines GLP-1, GIP and GCG receptor agonist activity in a single construct. The differentiated design of MBX 6180 is intended to provide a pharmacokinetic profile supporting once-monthly dosing. IND-enabling studies are now underway.
Obesity is a common condition in the United States, with more than 2 in 5 adults 20 and older (42.5%)1 being afflicted. A chronic condition, it can be caused by a variety of factors including, but not limited to, eating high-calorie, low nutrient foods and beverages, lack of physical activity, some medications, and genetics.
Screening for obesity is performed by healthcare providers using body mass index (BMI), which measures the percent of body fat in an individual. A person whose weight is higher than what is considered to be a normal weight for a given height is described as being overweight or having obesity.2 In the case of adults 20 and older, a BMI >30 is classified as obese and >40 is severely obese.
A high percentage of body fat can put an individual’s health at risk as it increases the likelihood for developing more than 200 health problems such as high blood pressure, type 2 diabetes, depression, cancer and heart disease – the leading cause of death in the United States. In fact, research shows that there has been a three-fold increase in obesity-related deaths from heart disease in the United States between 1999-2020.3
The biomedical, psychosocial, and economic consequences of obesity have substantial implications for the health and well-being of the U.S. population.4 There is also a bias to be addressed, as it is well documented that those who feel stigmatized by obesity can suffer extreme emotional distress and be subject to discrimination, which can lead to further negative health impacts, including depression and additional weight gain.5
While lifestyle changes may influence weight loss and reductions in BMI, obesity is a complex problem that often does not have a single solution. Whether behavioral, pharmacologic, or surgical, this epidemic may benefit from a holistic multifaceted approach.6
Our world-class technology platform was developed with the flexibility to tackle a variety of diseases that could benefit from more precise therapeutic options. We have an active research and design program, through which we have identified numerous additional candidates in both rare and prevalent diseases. These candidates are in various stages of pre-clinical development.
World-Class Peptide Platform
Explore what patients have to say and learn more about our current clinical trials and how MBX Biosciences is striving to make a difference for people living with hypoparathyroidism, post-bariatric hypoglycemia and obesity.
Patients